オリゴヌクレオチドの世界市場

出版：BCC Research（BCCリサーチ）　出版年月：2024年3月

Oligonucleotides: Global Markets

オリゴヌクレオチドの世界市場

お問合せ・ご注文　　出版社・価格・納期について

Report Highlights

The global market for oligonucleotides is expected to grow from $7.0 billion in 2023 and projected to reach $11.7 billion by the end of 2028, at a compound annual growth rate (CAGR) of 11.0% during the forecast period of 2023 to 2028.

オリゴヌクレオチドの世界市場は、2023 年の 70 億ドルから成長し、2023 年から 2028 年の予測期間中に年間平均成長率 (CAGR) 11.0% で、2028 年末までに 117 億ドルに達すると予測されています。

Summary:

The term oligonucleotide is derived from the Greek word oligo, which means small or few. The base length of the oligos is usually identified as “mer,” which means “part” in the Greek language. Oligonucleotides are short DNA/RNA strands. These can be made based on client requirements by solid phase chemical synthesis. They are made up of 13 to 25 bases to hybridize to complementary sequence. These oligos are primarily used in polymerase chain reaction (PCR) as a probe, but are also used in DNA based microarray techniques, Southern blot assay, FISH (Fluorescent In Situ Hybridization), and ASO analysis.

Relatively short nucleic acid fragments can be synthesized chemically with a well-defined structure or sequence in the oligonucleotide synthesis method. This process is very helpful in modern laboratory practice because it offers quick and affordable access to custom-made oligonucleotides with the desired sequence. It is also helpful for molecular diagnosis of various diseases, including infectious diseases like SARS-COV2 and hepatitis. It is also helpful for the diagnosis of cancer.

Along with its diagnostics and research uses, oligonucleotides are also being used as therapeutic drugs for a wide range of diseases. This type of drug focuses on the gene silencing technique, as well as splice modulation and gene activation modalities for treatment. Oligonucleotide drugs offer personalized medicine approaches to target the specific gene sequences responsible for the occurrence of a specific disease. In 1998, the first oligonucleotide drug, Vitravene (fomivirsen) got approval for the treatment of cytomegalovirus retinitis (CMV). To date 15 drugs have received FDA approval for therapeutic usage for the treatment of liver, spinal cord, and skeletal muscle-based disorders. For oncology treatment, more than 200 oligonucleotide drugs are in various phases of clinical trials.

The global market for oligonucleotides was valued at $6.3 billion in 2022 and is expected to reach $11.7 billion by 2028.

Report Scope:

This report covers the worldwide market for oligonucleotide synthesis, which consists of four main product types: oligonucleotide drugs, synthesized oligos, equipment and reagents, and services. Based on application, the market for oligonucleotide synthesis is divided into research and diagnostics and therapeutics.
By geography, the market in this report is divided into four regions: North America, Europe, Asia-Pacific, and Rest of the World (RoW). For market estimates, data has been provided for 2022 as the base year, with forecasts for 2023 through 2028.

The report also covers approved drugs, the oligonucleotide synthesis process, innovative research, opportunities within the market and profiles of leading companies in the oligonucleotide synthesis industry.

Report Synopsis

Report Includes:

– 31 data tables and 48 additional tables
– Overview and an analysis of the global markets for oligonucleotides
– Analyses of the global market trends, with historical market revenue data (sales figures) from 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
– A discussion of the current and future market potential of oligonucleotide synthesis, as well as the competitive landscape, market dynamics, ongoing research, and trends in market growth
– Estimate of the market size and revenue forecasts, and a corresponding market share analysis based on product type, application and region
– Coverage of the total market for oligonucleotide synthesis, which includes RNA oligos, DNA oligos, and the platform services offered by many companies
– Overview of the sustainability trends and ESG developments, with an emphasis on consumer attitudes, ESG score analysis, and the ESG practices followed by leading companies
– A look at the recent developments in the market and emerging technologies
– An analysis of the key patents and recent clinical trials on oligonucleotide synthesis-based products and applications
– Competitive intelligence, including the major vendors’ market shares, recent M&A activity, and venture funding outlook
– Profiles of the leading global players, including Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Integrated DNA Technologies, Inc., Eurofins Scientific, and Biolytic Lab Performance Inc.

Table of Contents

Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Insights
Chapter 2 Market Overview
Definitions
History of Oligonucleotide Synthesis
First Dinucleotide
Solid Phase Synthesis
Types of Oligonucleotides
DNA Probes
RNA Probes
Oligonucleotide Synthesis Processes
Solid Phase Chemical Synthesis
Alternative Forms of Oligonucleotide Synthesis
Versatile Functions of Synthetic Oligonucleotides
Regulatory Paths for Oligotherapeutics
Animal Models and Studies
Role of Regulatory Authorities
Chapter 3 Market Dynamics
Drivers
Increasing Use of Synthesized Oligos in Therapeutic Applications
Rising Government Investments for Synthetic Biology and Genome Projects
Growing Focus on Personalized Medicine
Restraints
Complexities Associated with Oligos
Lack of Clear Regulatory Infrastructure
Opportunities
Expansion of Companies
Emerging Applications in Various Fields
Chapter 4 Emerging Technologies and Developments
Overview
DNA Synthesizers
Emerging Technologies
Microfluidics Approach
Enzymatic De Novo DNA Synthesis
Chapter 5 Market Segmentation Analysis
Segmentation Breakdown
Global Market for Oligonucleotide Synthesis, by Product Type
Oligonucleotide Drugs
Equipment and Reagents
Synthesized Oligos
Services
Global Market for Oligonucleotide Synthesis, by Application
Research
Diagnostics and Therapeutics
Geographic Breakdown
Global Market for Oligonucleotide Synthesis, by Region
North America
Europe
Asia-Pacific
Rest of the World
Chapter 6 Competitive Intelligence
Competitive Landscape
Patent Analysis
M&A Analysis
Funding Outlook
Industry Structure
Chapter 7 ESG Development
Introduction to ESG
Assessing the Sustainability of the Oligonucleotide Manufacturing Process
Assessment Against the 12 Principles of Green Chemistry
Process Mass Intensity (PMI) Assessment
Assessment of Compounds Used in Oligonucleotide Manufacture
ESG Performance in Market
Concluding Remarks from BCC
Chapter 8 Appendix
Methodology
Company Profiles
AGILENT TECHNOLOGIES INC.
BIOLEGIO B.V.
BIOLYTIC LAB PERFORMANCE INC.
EUROFINS SCIENTIFIC
GENSCRIPT
INTEGRATED DNA TECHNOLOGIES INC.
LC SCIENCES
LGC GROUP
MERCK KGAA
MICROSYNTH AG
THERMO FISHER SCIENTIFIC INC.

List Of Tables

Summary Table : Global Market for Oligonucleotides, by Region, Through 2028
Table 1 : History of Oligonucleotide Therapeutics, 1964-2013
Table 2 : Comparison of Oligonucleotide and Polynucleotide
Table 3 : Yield, Length and Coupling Efficiency of Oligonucleotide
Table 4 : List of Approved Oligonucleotide Therapeutics, 2023
Table 5 : Global Market for Oligonucleotide Synthesis, by Product Type, Through 2028
Table 6 : Global Market for Oligonucleotide Drugs, by Region, Through 2028
Table 7 : Revenue Generated, by Few Oligonucleotide Drugs, 2022
Table 8 : Global Market for Equipment and Reagents, by Region, Through 2028
Table 9 : Global Market for Synthesized Oligos, by Region, Through 2028
Table 10 : Pricing of Oligo Pools, by Twist Bioscience
Table 11 : Pricing for Oligo pools, by GenScript
Table 12 : Global Market for Services, by Region, Through 2028
Table 13 : Global Market for Oligonucleotide Synthesis, by Application, Through 2028
Table 14 : Global Market for Research Applications, by Region, Through 2028
Table 15 : Global Market for Diagnostic and Therapeutic Applications, by Region, Through 2028
Table 16 : Global Market for Oligonucleotide Synthesis, by Region, Through 2028
Table 17 : North American Market for Oligonucleotide Synthesis, by Product Type, Through 2028
Table 18 : North American Market for Oligonucleotide Synthesis, by Application, Through 2028
Table 19 : North American Market for Oligonucleotide Synthesis, by Country, Through 2028
Table 20 : European Market for Oligonucleotide Synthesis, by Product Type, Through 2028
Table 21 : European Market for Oligonucleotide Synthesis, by Application, Through 2028
Table 22 : European Market for Oligonucleotide Synthesis, by Country, Through 2028
Table 23 : Asia-Pacific Market for Oligonucleotide Synthesis, by Product Type, Through 2028
Table 24 : Asia-Pacific Market for Oligonucleotide Synthesis, by Application, Through 2028
Table 25 : Asia-Pacific Market for Oligonucleotide Synthesis, by Country, Through 2028
Table 26 : RoW Market for Oligonucleotide Synthesis, by Product Type, Through 2028
Table 27 : RoW Market for Oligonucleotide Synthesis, by Application, Through 2028
Table 28 : Top Oligonucleotide Synthesis Manufacturers, 2022
Table 29 : Select Patents on Oligonucleotide Synthesis Published in 2020
Table 30 : Select Patents on Oligonucleotide Synthesis Published in 2021
Table 31 : Select Patents on Oligonucleotide Synthesis Published in 2022
Table 32 : Select Patents on Oligonucleotide Synthesis Published in 2023
Table 33 : Major Strategic Alliances in Oligonucleotide Synthesis Industry, 2023
Table 34 : Top Deals in Oligonucleotide Synthesis Industry, 2023
Table 35 : Antisense Oligonucleotides Cancer Therapeutics in Clinical Trials
Table 36 : siRNA Cancer Therapeutics in Clinal Trials
Table 37 : miRNA Cancer Therapeutics in Clinal Trials
Table 38 : Assessment of the Oligonucleotide Manufacturing Process Against the 12 Principles of Green Chemistry
Table 39 : Assessment of Compounds Used in Oligonucleotide Manufacture against the CHEM21 Solvent Guide
Table 40 : Key Focus Areas in ESG Metrics
Table 41 : ESG Rankings for Oligonucleotide Companies, 2023*
Table 42 : Acronyms Used in this Report
Table 43 : Agilent Technologies Inc.: Company Snapshot
Table 44 : Agilent Technologies Inc.: Financial Performance, F.Y. 2022 and 2023
Table 45 : Agilent Technologies Inc.: Product Portfolio
Table 46 : Agilent Technologies Inc.: News/Key Developments, 2022-2023
Table 47 : Biolegio B.V.: Company Snapshot
Table 48 : Biolegio B.V.: Product Portfolio
Table 49 : Biolytic Lab Performance Inc.: Company Snapshot
Table 50 : Biolytic Lab Performance Inc.: Product Portfolio
Table 51 : Biolytic Lab Performance Inc.: News/Key Developments, 2021
Table 52 : Eurofins Scientific: Company Snapshot
Table 53 : Eurofins Scientific: Financial Performance, FY 2022 and 2023
Table 54 : Eurofins Scientific: Product Portfolio
Table 55 : GenScript: Company Snapshot
Table 56 : GenScript: Financial Performance, FY 2021 and 2022
Table 57 : GenScript: Product Portfolio
Table 58 : GenScript: News/Key Developments, 2021-2023
Table 59 : Integrated DNA Technologies Inc.: Company Snapshot
Table 60 : Integrated DNA Technologies Inc.: Product Portfolio
Table 61 : Integrated DNA Technologies Inc.: News/Key Developments, 2021-2023
Table 62 : L.C. Sciences: Company Snapshot
Table 63 : L.C. Sciences: Product Portfolio
Table 64 : LGC Group: Company Snapshot
Table 65 : LGC Group: Financial Performance, FY 2022 and 2023
Table 66 : LGC Group: Product Portfolio
Table 67 : LGC Group: News/Key Developments, 2023
Table 68 : Merck KGaA: Company Snapshot
Table 69 : Merck KGaA: Financial Performance, FY 2022 and 2023
Table 70 : Merck KGaA: Product Portfolio
Table 71 : Merck KGaA: News/Key Developments, 2021
Table 72 : Microsynth AG: Company Snapshot
Table 73 : Microsynth AG: Product Portfolio
Table 74 : Microsynth AG: News/Key Developments, 2021-2023
Table 75 : Thermo Fisher Scientific Inc.: Company Snapshot
Table 76 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
Table 77 : Thermo Fisher Scientific Inc.: Product Portfolio
Table 78 : Thermo Fisher Scientific Inc.: News/Key Developments, 2021-2023

List Of Figures

Summary Figure : Global Market Shares of Oligonucleotides, by Region, 2022
Figure 1 : History of the Solid-Phase Synthesis of Oligonucleotide
Figure 2 : Summary of Solid-Phase Oligonucleotide Synthesis Cycle
Figure 3 : Classification of Synthetic Oligonucleotides
Figure 4 : Dynamics of the Global Market for Oligonucleotides
Figure 5 : Global Market Shares of Oligonucleotide Synthesis, by Product Type, 2022
Figure 6 : Global Market for Oligonucleotide Drugs, 2020-2028
Figure 7 : Global Market for Oligonucleotide Drugs, by Region, 2020-2028
Figure 8 : Global Market for Equipment and Reagents, 2020-2028
Figure 9 : Global Market for Equipment and Reagents, by Region, 2020-2028
Figure 10 : Global Market for Synthesized Oligos, 2020-2028
Figure 11 : Global Market for Synthesized Oligos, by Region, 2020-2028
Figure 12 : Global Market for Services, 2020-2028
Figure 13 : Global Market for Services, by Region, 2020-2028
Figure 14 : Global Market Shares of Oligonucleotide Synthesis, by Application, 2022
Figure 15 : Global Market for Research Applications, 2020-2028
Figure 16 : Global Market for Research Applications, by Region, 2020-2028
Figure 17 : Global Market for Diagnostic and Therapeutic Applications, 2020-2028
Figure 18 : Global Market for Diagnostics and Therapeutics, by Region, 2020-2028
Figure 19 : Global Market for Oligonucleotide Synthesis, by Region, 2020-2028
Figure 20 : North American Market Shares of Oligonucleotide Synthesis, by Product Type, 2022
Figure 21 : North American Market Shares of Oligonucleotide Synthesis, by Application, 2020
Figure 22 : North American Market Shares of Oligonucleotide Synthesis, by Country, 2022
Figure 23 : European Market Shares of Oligonucleotide Synthesis, by Product Type, 2022
Figure 24 : European Market Shares of Oligonucleotide Synthesis, by Application, 2022
Figure 25 : European Market Shares of Oligonucleotide Synthesis, by Country, 2022
Figure 26 : Asia-Pacific Market Shares of Oligonucleotide Synthesis, by Product Type, 2022
Figure 27 : Asia-Pacific Market Shares of Oligonucleotide Synthesis, by Application, 2022
Figure 28 : Asia-Pacific Market Shares of Oligonucleotide Synthesis, by Country, 2022
Figure 29 : RoW Market Shares of Oligonucleotide Synthesis, by Product Type, 2022
Figure 30 : RoW Market Shares of Oligonucleotide Synthesis, by Application, 2022
Figure 31 : Drug Manufacturer Shares of Oligonucleotides, 2022
Figure 32 : Patent Applications and Patents Granted, 2000-2023
Figure 33 : Venture Capital Deals Including Corporate Pharma and Biotech Investors, by Year, 2010-2023
Figure 34 : How a Strong ESG Proposition Benefits Businesses
Figure 35 : ESG Adoption Level across Industries
Figure 36 : Agilent Technologies Inc.: Revenue Share, by Business Unit, FY 2023
Figure 37 : Agilent Technologies Inc.: Revenue Share, by Country/Region, FY 2023
Figure 38 : Eurofins Scientific: Revenue Share, by Country/Region, FY 2023
Figure 39 : GenScript: Revenue Share, by Business Unit, FY 2022
Figure 40 : GenScript: Revenue Share, by Country/Region, FY 2022
Figure 41 : LGC Group: Revenue Shares, by Business Unit, F.Y. 2023
Figure 42 : LGC Group: Revenue Share, by Country/Region, FY 2023
Figure 43 : Merck KGaA: Revenue Share, Business Unit, FY 2023
Figure 44 : Merck KGaA: Revenue Share, by Country/Region, FY 2023
Figure 45 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2023
Figure 46 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2023